Enochian

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Enochian Biosciences Inc. (ENOB)

Retrieved on: 
Thursday, July 28, 2022
Legal, Professional Services, Steps, Crime, Felony, Hindenburg, Theft, Hepatitis B virus, Person, China Biologic Products, Securities Exchange Act of 1934, HIV, U.S. Department of Justice Office of Legislative Affairs, NASDAQ, Fraud, Cancer, News, U.S. Department of Defense Strategy for Operating in Cyberspace, Technology, Company, Science, Justice, Hindenburg Research, Complaint, Coronavirus, ENOB, Enochian

The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Enochian Biosciences Inc. (NASDAQ: ENOB) securities between September 24, 2020 and May 31, 2022, for violations of the Securities Exchange Act of 1934.

Key Points: 
  • The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Enochian Biosciences Inc. (NASDAQ: ENOB) securities between September 24, 2020 and May 31, 2022, for violations of the Securities Exchange Act of 1934.
  • If you would like more information about Enochian Biosciences Inc.'s misconduct, click here .
  • On May 25, 2022, the U.S. Department of Justice announced that Gumrukcu had been arrested and charged in a murder-for-hire conspiracy.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

ENOCHIAN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Enochian Biosciences, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 28, 2022
Class Action Lawsuit, Professional Services, Legal, Seraph, Identity theft, Court, For Hire, Hindenburg, Jeanne Eagels, Telephone, Central District, Hepatitis B virus, Person, China Biologic Products, HIV, Risk, U.S. Department of Justice Office of Legislative Affairs, NASDAQ, Fraud, Cancer, News, Office of Inspector General, U.S. Department of Health and Human Services, Technology, Company, P.C, Science, Defendant, G-Technology, Lists of schools in England, District court, Justice, Hindenburg Research, LLC, SRI, Coronavirus, Private investigator, Renewable energy, Pharmaceutical industry, Enochian

Investors have until September 26, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until September 26, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On May 25, 2022, the U.S. Department of Justice announced that Gumrukcu had been arrested and charged in a murder-for-hire conspiracy.
  • On this news, Enochians stock price fell $2.17 per share, or 36.97%, to close at $3.70 per share on May 25, 2022.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

INVESTOR ALERT: Enochian Biosciences Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ENOB

Retrieved on: 
Wednesday, July 27, 2022
Class Action Lawsuit, Professional Services, Legal, Seraph, Private Securities Litigation Reform Act, Identity theft, Company, Hindenburg, For Hire, History, China Biologic Products, Securities Exchange Act of 1934, Risk, List of life sciences, NASDAQ, Fraud, Cancer, News, Technology, Science, G-Technology, SEC, Lawyer, Lists of schools in England, Justice, HBV, Hindenburg Research, LLC, United States Department of Justice, SRI, HIV, Coronavirus, Enron, Tobacco, Pharmaceutical industry, Enochian

The Enochian Biosciences class action lawsuit captioned Chow v. Enochian Biosciences Inc., No.

Key Points: 
  • The Enochian Biosciences class action lawsuit captioned Chow v. Enochian Biosciences Inc., No.
  • A lead plaintiff acts on behalf of all other class members in directing the Enochian Biosciences class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the Enochian Biosciences class action lawsuit.
  • An investors ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Enochian Biosciences class action lawsuit.

ENOB Class Action Complaint Filed: Johnson Fistel, Globally-Recognized Law Firm Encourages Shareholders to Submit Their Enochian Losses

Retrieved on: 
Tuesday, July 26, 2022
LLP, GLOBE, Court, Learning, SAN, Risk, NASDAQ, Fraud, Company, Defendant, G-Technology, Lists of schools in England, SRI, Security (finance), Tobacco, Enochian

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Enochian Biosciences Inc. (Enochian or the Company) (NASDAQ: ENOB).

Key Points: 
  • SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Enochian Biosciences Inc. (Enochian or the Company) (NASDAQ: ENOB).
  • The class action is on behalf of shareholders who purchased Enochian securities between September 24, 2020 and May 31, 2022, both dates inclusive (the Class Period).
  • An investor's ability to share any potential future recovery of the Enochian class action lawsuit is not dependent upon serving as lead plaintiff.
  • Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia.

Pomerantz Law Firm Announces the Filing of a Class Action Against Enochian Biosciences Inc. and Certain Officers and Directors – ENOB

Retrieved on: 
Tuesday, July 26, 2022
Seraph, LLP, Identity theft, Company, GLOBE, Court, For Hire, Hindenburg, Central District, Lists of action films, Hepatitis B virus, Person, China Biologic Products, Securities Exchange Act of 1934, HIV, U.S. Department of Justice Office of Legislative Affairs, NASDAQ, Fraud, Cancer, News, SEC Rule 10b-5, Ext, Office of Inspector General, U.S. Department of Health and Human Services, Technology, Science, Defendant, G-Technology, Lists of schools in England, Complaint, District court, Justice, Hindenburg Research, LLC, SRI, Pomerantz, Coronavirus, Pharmaceutical industry, Private investigator, Renewable energy, Enochian

NEW YORK, July 26, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Enochian Biosciences Inc. (Enochian or the Company) (NASDAQ: ENOB) and certain of its officers and directors.

Key Points: 
  • NEW YORK, July 26, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Enochian Biosciences Inc. (Enochian or the Company) (NASDAQ: ENOB) and certain of its officers and directors.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Is Investigating Enochian, Corcept, Cassava, and Hannon Armstrong and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, July 26, 2022
Death, Sale, United, Experiment, GLOBE, Health Insurance Portability and Accountability Act, Research, HIPAA, U.S. Securities and Exchange Commission, Securitization, PLOS One, NYSE, Muddy Waters Research, CORT, The New York Times, Cassava, Income, Corcept Therapeutics, NASDAQ, Accountability Act, GAAP, News, Company, Record, District, HASI, Online gambling, Security (finance), Audit, Enochian, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022.
  • Dr. Gumrukcu sold 253,493 shares of Enochian stock on May 18, 2022, for a total value of over $2 million.
  • For more information on the Hannon Armstrong investigation go to: https://bespc.com/cases/HASI
    About Bragar Eagel & Squire, P.C.

Enochian BioSciences Appoints Dr. Richard Whitley As Senior Scientific Advisor

Retrieved on: 
Monday, July 25, 2022
Virus, Division, University, GLOBE, A Call for Unity, American Pediatric Society, Hijack, Drug discovery, CEO, SEC, International Advisory and Monitoring Board, Research, National Institute, COVID-19, Nature, NASDAQ, Virology, UAB, ISCB Senior Scientist Award, Gene therapy, Company, Senior advisor, Patient, List, Department, Annual report, National Institute of Allergy and Infectious Diseases, The Pediatric Infectious Disease Journal, Infection, RNA, Pharmaceutical industry, Enochian, Pediatrics, COVID

LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)Today, Enochian BioSciences (the Company) announced that Dr. Richard (Rich) Whitley, M.D., of the University of Alabama at Birmingham (UAB), will become the Companys Senior Scientific Advisor.

Key Points: 
  • LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)Today, Enochian BioSciences (the Company) announced that Dr. Richard (Rich) Whitley, M.D., of the University of Alabama at Birmingham (UAB), will become the Companys Senior Scientific Advisor.
  • A Distinguished Professor of Pediatrics at UAB, Dr. Whitley brings decades of virology research experience to the Company, including clinical research experience to develop antiviral therapies.
  • "We are incredibly excited to bring on Dr. Whitley as a Senior Scientific Advisor," said Enochian's CEO Dr. Mark Dybul.
  • "Rich is not only a talented clinician, but also a well noted researcher whose experience and expertise will be instrumental in our research pipelines.

Bragar Eagel & Squire, P.C. Is Investigating Enochian, Corcept, Rollins, and the WWE and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 21, 2022
Hush, Death, Sale, The Wall Street Journal, United, GLOBE, Documentation, WWE, Health Insurance Portability and Accountability Act, Rollins, U.S. Securities and Exchange Commission, HIPAA, Female, CEO, NYSE, SEC, CORT, Board, Period. End of Sentence., Corcept Therapeutics, NASDAQ, Accountability Act, Civilian Complaint Review Board, News, Review, Company, P.C, Record, Annual report, District, McMahon, Online gambling, Audit, Animal, Enochian

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022.
  • Dr. Gumrukcu sold 253,493 shares of Enochian stock on May 18, 2022, for a total value of over $2 million.
  • For more information on the WWE investigation go to: https://bespc.com/cases/WWE
    About Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Is Investigating Enochian, Corcept, Rollins, and Target and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, July 16, 2022
SEC, News, U.S. Securities and Exchange Commission, Rollins, Review, GLOBE, United, Income, NYSE, Corcept Therapeutics, Record, District, Health Insurance Portability and Accountability Act, Documentation, NASDAQ, Sale, Company, HIPAA, TGT, Death, Target Corporation, Annual report, Accountability Act, Period. End of Sentence., Target, CORT, Private investigator, Online gambling, Audit, Renewable energy, Enochian, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022.
  • Dr. Gumrukcu sold 253,493 shares of Enochian stock on May 18, 2022, for a total value of over $2 million.
  • For more information on the Target investigation go to: https://bespc.com/cases/TGT
    About Bragar Eagel & Squire, P.C.

Kirby McInerney LLP Continues Investigation of Shareholder Claims on Behalf of Enochian Biosciences, Inc. (ENOB) Investors

Retrieved on: 
Friday, July 15, 2022
Research report, Hindenburg, News, The Wall Street Journal, Cancer, Review, GLOBE, Kirby, U.S. Department of Justice Office of Legislative Affairs, Hindenburg Research, NASDAQ, Company, FBI, Privacy Office of the U.S. Department of Homeland Security, Justice, Private investigator, Pharmaceutical industry, Enochian

NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Enochian Biosciences, Inc. (Enochian or the Company) (NASDAQ: ENOB ).

Key Points: 
  • NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Enochian Biosciences, Inc. (Enochian or the Company) (NASDAQ: ENOB ).
  • The investigation concerns whether Enochian has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Enochian is a biopharmaceutical company that focuses on identifying, developing, manufacturing, and commercializing gene-modified cell therapy.
  • Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.